Supplements & micronutrients

Cardiocalm withdrawn from the market? What is really going on, and the alternatives

16 min read 22 Nov 2026 Supplements & micronutrients
Cardiocalm withdrawn from the market? What is really going on, and the alternatives

The short answer

No official source consulted on 22/11/2026 documents a withdrawal of Cardiocalm. The French public medicines database (Ministry of Health, ANSM, HAS) still lists its registration with the status “valid”, with two pack sizes (40 and 80 tablets) and a record updated on 03/11/2026. It mentions no discontinuation, no batch recall and no safety alert. There is therefore no “reason for withdrawal” to report: we are not making one up.

If you can no longer find Cardiocalm at the pharmacy, the most likely cause is a local shortage or a stock-out at your wholesaler, which only your pharmacy or the manufacturer can confirm. This article sets out what is actually known, then the alternatives for stress and sleep, with their level of evidence.

Probable lead for the rumour: a decision of 24 November 2010 by the Director General of Afssaps (the former French medicines safety agency, now the ANSM) banned advertisements for Cardiocalm aimed at doctors. It targets mailings and brochures from the laboratory, not the sale of the medicine: details below.

This article is for information only and does not replace medical advice. Palpitations should first be examined by a doctor.

Has Cardiocalm been withdrawn from the market? What the sources show

What we checked Result
Authorisation status “Valid” in the public medicines database, record updated on 03/11/2026
Pack sizes 40 tablets (marketing declaration of 19/01/1965) and 80 tablets (03/04/2006)
Discontinuation No notice on the record
ANSM alert or recall None found in our searches
Vidal Listed as “marketed” (manufacturer record updated on 06/10/2023)
Public medicines database (medicaments.gouv.fr), consulted on 22/11/2026; Vidal.

Two honest limitations. First, a “valid” record does not prove that the pack is available everywhere today: a medicine can remain authorised while out of stock. Second, we could not consult the full list of discontinuations published by the ANSM (the French medicines agency), and we found no press release from the manufacturer. If the discontinuation happened after 03/11/2026, it does not yet appear in these sources.

Where might the rumour come from? We cannot say for certain, but three public facts may have fuelled the confusion. The first: Cardiocalm is not reimbursed (free pricing). The second: in 2005 the HAS Transparency Committee (Commission de la transparence) judged its medical benefit (service médical rendu) insufficient for its indications (opinion of 13 April 2005, reassessment of the medical benefit). An insufficient medical benefit does not mean the product is dangerous, only that it does not justify reimbursement by the French national health insurance (Assurance maladie). The third: a 2010 decision bans advertisements for Cardiocalm, which is not a ban on the medicine (see the dedicated section below). Finally, other medicines have indeed been withdrawn for safety reasons, such as Pneumorel (fenspiride) because of a risk of heart rhythm disorders, but this has no connection with Cardiocalm.

The 2010 advertising ban: what the decision actually says

This is the only public decision “against Cardiocalm” that we found, and it is easy to misread. It is the decision of 24 November 2010 banning advertisements for a medicinal product, published in the Journal officiel of 19 December 2010 (text no. 15, NOR ETSM1020278S).

Point What the decision says
Author The Director General of the Agence française de sécurité sanitaire des produits de santé (Afssaps, the French medicines safety agency, since replaced by the ANSM)
Date 24 November 2010, published in the Journal officiel (the French official gazette) of 19 December 2010
Subject To ban advertisements for the medicinal product Cardiocalm, distributed by the Pharmastra laboratory as two mailshots sent to doctors: each mailing included a letter and a brochure from the “Objectif zéro stress” series
First ground The documents presented Cardiocalm as a preventive treatment for anxiety and depression, whereas the authorisation covers only disorders of cardiac erethism (an abnormally excitable heart) in adults (healthy heart) and the symptomatic treatment of neurotonic states, notably minor sleep disorders
Second ground The letters and brochures attributed to the product heart-regulating and antiarrhythmic properties and efficacy in certain manifestations of heart failure, which the summary of product characteristics does not recognise; it recognises only cardiac erethism and describes the medicine as a herbal medicine with a sedative aim
Operative provision The advertisements in question for Cardiocalm are banned (Article L. 5122-2 of the French Public Health Code)
Légifrance (the French government legal database), JORF no. 0294 of 19 December 2010, text no. 15 (JORFTEXT000023247365).

What the decision does not say:

  • it neither withdraws nor suspends the medicine’s authorisation: it concerns two promotional documents, not the product sold in pharmacies;
  • it reports no danger and no side effect: the criticism is that the advertising went beyond the authorised indications;
  • it was aimed at the doctors who received the mailshots, not at the general public.

The second ground echoes a point already noted by the HAS in 2005: Cardiocalm has no indication in heart failure. A title that begins with “banning” and names Cardiocalm can be taken for a ban on the medicine itself: this is a probable lead for the rumour, but an editorial hypothesis, and we cannot say that it is its origin. One last detail: the decision cites a tablet containing 100 mg of extract, whereas the current summary of product characteristics states 70 mg (the summary sheet in the public database still shows 100 mg). We draw no conclusion from this.

What Cardiocalm is: composition and status

Cardiocalm is a traditional herbal medicinal product, sold without a prescription by the Pharmastra laboratory. It was registered through the national procedure on 04/07/2017 as a herbal medicine. Its active ingredient is a dry extract of hawthorn leaf and flower (Crataegus laevigata or C. monogyna), extracted with 60% ethanol, with a drug-to-extract ratio of 4 to 7:1. The summary of product characteristics states 70 mg of extract per tablet (the summary sheet in the public database shows 100 mg, an internal inconsistency in the database).

Its indications, restricted to adults and based solely on long-standing use:

  • relief of temporary heart symptoms of nervous origin (palpitations, an exaggerated awareness of the heartbeat linked to mild anxiety), after a doctor has ruled out a serious condition;
  • states of mild nervous tension and minor sleep disorders.

According to the summary of product characteristics, you should see a doctor if symptoms last longer than 2 weeks. It is not recommended during pregnancy and breastfeeding, or under 18. No side effect is described in the leaflet, and no interaction study has been carried out. The excipients include the colouring E127 (erythrosine).

Cardiocalm reviews: what these indications are really worth

We have not tested it, and we do not publish user reviews. What we can say is what the authorities say. The Cardiocalm file rests on traditional use, not on clinical trials demonstrating efficacy. This is true of many herbs with a traditional use: for hawthorn, the European Medicines Agency (EMA) notes a lack of sufficient clinical studies for uses linked to nervousness and sleep, and relies partly on reference works. The HAS opinion of 2005 points in the same cautious direction, with an insufficient medical benefit.

In practical terms: if someone feels better with this product, nothing prevents them from continuing after medical advice, but it cannot be claimed that it treats palpitations or that it does better than a placebo. Above all, it must never be used to mask a cardiac symptom that has not been investigated.

What are the benefits of Cardiocalm?

These are traditional-use indications, not demonstrated effects. The leaflet (public medicines database, updated 04/07/2017) presents Cardiocalm as a traditional herbal medicinal product used:

  • to relieve temporary heart symptoms of nervous origin (palpitations, an exaggerated awareness of the heartbeat linked to mild anxiety), after a doctor has ruled out any serious condition;
  • in states of mild nervous tension and minor sleep disorders.

The leaflet states that this use rests on long-standing use. Adult dose, taken orally with water: 1 to 2 tablets per dose, up to 6 a day for temporary heart symptoms and mild nervous tension; 1 tablet with the evening meal and 1 to 2 at bedtime for minor sleep disorders. If symptoms persist for more than 2 weeks, see a doctor.

What the HAS thought in 2005 (opinion of the Transparency Committee of 13 April 2005, the product then being reimbursed at 65%): the efficacy of Cardiocalm in its indications is poorly established, as is the balance between efficacy and side effects, and the medical benefit is insufficient. The Committee notes, however, that the medicine appears well tolerated, that the conditions concerned are not serious, and that the first measures are lifestyle and dietary: stopping smoking and alcohol, cutting down on stimulants, suitable physical activity, regular and sufficient sleep hours. It adds that it is in no way essential to use a medicine, and that, according to some experts, this type of herbal medicine can be an alternative to anxiolytics and hypnotics in minor forms.

Are there any dangers in taking Cardiocalm? When not to take it

What the leaflet, the summary of product characteristics (SmPC) and the HAS say:

  • Side effects: the leaflet states that no side effect is known to date, and the SmPC that no case of overdose has been reported.
  • Tolerance: in 2005, the HAS judged the medicine well tolerated. It also cited studies on other hawthorn extracts, at doses higher than that of Cardiocalm: in the largest (3,664 patients, 8 weeks), 48 people (1.3%) reported side effects, such as hot flushes, stomach pain or palpitations, with treatment stopped in 19.
  • Missing data: the SmPC states that no interaction study has been carried out, that adequate reproductive toxicity studies have not been done and that no carcinogenicity study has been carried out. In vitro genotoxicity tests (Ames test) showed no mutagenic effect.
  • The main risk remains false reassurance about a cardiac symptom that deserves an examination.
Situation What the leaflet and SmPC say
Allergy to hawthorn or to another component (including erythrosine E127 and titanium dioxide E171) Never take Cardiocalm
Under 18 Not recommended
Pregnancy, breastfeeding Not recommended: safety of use has not been established
Palpitations that have not been investigated To be taken only after a doctor has ruled out a serious condition; the HAS spoke of a healthy heart confirmed by a clinical assessment and an electrocardiogram
Swollen ankles or legs, pain in the heart region that may spread to the arms, upper abdomen or neck, breathlessness Seek immediate advice from a doctor or pharmacist
Symptoms that get worse or last longer than 2 weeks See a doctor
You are taking other medicines No interaction study: ask your pharmacist for advice
Public medicines database: Cardiocalm leaflet and SmPC, film-coated tablet (CIS code 69860842); HAS, opinion of 13 April 2005.

Palpitations: see a doctor before looking for an alternative

The Cardiocalm text itself says so: it is intended only for symptoms felt as nervous in origin, once a serious condition has been ruled out. Palpitations have many causes, benign (stress, caffeine, lack of sleep) or not (rhythm disorders, thyroid, anaemia). A doctor can work this out with an examination and often an electrocardiogram.

Seek help quickly, or call the emergency services, if you have chest pain, difficulty breathing, feel faint or pass out, or have swollen ankles or legs, signs that the Cardiocalm leaflet itself lists as urgent.

What is the equivalent of Cardiocalm?

There is no equivalent in the sense of a generic: the public medicines database indicates that Cardiocalm belongs to no generic group. Depending on what is meant by “equivalent”, there are three avenues:

  • another hawthorn-based product: it is the same plant, but the dose, the type of extract and the excipients may differ. The EMA recognises the traditional use of hawthorn leaf and flower (see below), for lack of sufficient clinical studies. We do not name a brand, because we have not compared the leaflets: ask your pharmacist for advice;
  • another supporting herb for nervousness and light sleep problems, such as lemon balm or passionflower (see the table below);
  • measures without medicines, which the HAS listed first in 2005: stopping smoking and alcohol, fewer stimulants, suitable physical activity, regular sleep hours.

Alternatives to Cardiocalm for stress and sleep: the real level of evidence

Once palpitations have been investigated, here are the most common options for nervous tension and light sleep problems, with what the studies show.

Option What the sources say Level of evidence
Magnesium Review of 18 studies (Boyle, 2017): positive results in about half of the studies in people who were already anxious, but the quality of the evidence was judged low. A trial in 46 elderly people with insomnia (500 mg per day, 8 weeks) improved sleep time. Low to moderate, small trials
Hawthorn The EMA recognises a traditional use (nervousness, light sleep problems), for lack of sufficient clinical studies. Traditional use
Lemon balm The EMA recognises a traditional use for mild stress and help with falling asleep; one small study cited had design flaws. Traditional use
Passionflower Cochrane (2007): only 2 studies, 198 participants, too few to conclude. Review of 9 trials (Janda, 2020): reduced anxiety in most, with a less clear effect in mild anxiety. Promising but limited
EMA, HMPC (hawthorn, lemon balm); Boyle et al., Nutrients 2017; Abbasi et al., J Res Med Sci 2012; Miyasaka et al., Cochrane 2007; Janda et al., Nutrients 2020.

Magnesium: the best studied, with modest results

This is the alternative with the most data, and the easiest to check: you can start by looking at your diet. Our guide to foods high in magnesium and the one on magnesium, its benefits and the signs of deficiency help you see whether your intake is sufficient. If you choose a supplement, read the actual dose of elemental magnesium rather than the weight of the salt: that is the purpose of our best magnesium comparison. Stay within the limits: see our guide on too much magnesium.

Hawthorn, lemon balm, passionflower: supporting herbs

What these three herbs have in common is that they are recognised mainly for their traditional use. That is enough for a herbal tea or a supporting capsule against mild nervousness, but not to treat an established sleep disorder or genuine anxiety. For lemon balm, the EMA says to see a doctor if symptoms persist beyond 2 weeks. Avoid self-medication during pregnancy and breastfeeding, in children, or if you are already taking a treatment: ask your pharmacist for advice.

To compare products, see our best sleep supplement comparison (it points out that melatonin saves about 7 minutes) and, for an adaptogenic approach, the best ashwagandha comparison.

What also helps, without supplements

Diet affects stress and sleep: see diet and stress management and foods for restorative sleep.

Frequently asked questions

Has Cardiocalm been withdrawn from the market?

No official source consulted on 22/11/2026 indicates a withdrawal. The public medicines database still shows it with the status “valid”, with two pack sizes. To find out whether it is available near you, ask your pharmacy.

Why was Cardiocalm withdrawn?

The reason is not documented, since no withdrawal has been established. The only public decision found banned, in 2010, advertisements aimed at doctors, not the medicine. We are not making one up: if it has been discontinued, the Pharmastra laboratory or the ANSM can confirm it.

Is Cardiocalm dangerous?

No ANSM safety alert was found, and the leaflet describes no known side effect (see the section on dangers and contraindications). The main risk is false reassurance about a cardiac symptom that deserves an examination.

Is Cardiocalm reimbursed?

No, the public database indicates free pricing with no reimbursement.

What does Cardiocalm contain?

A dry extract of hawthorn leaf and flower, 70 mg per tablet according to the summary of product characteristics, with excipients including the colouring E127.

What is an alternative to Cardiocalm for palpitations?

First, a medical consultation: no supplement replaces a diagnosis. Then, for stress and light sleep problems, magnesium, lemon balm, passionflower or hawthorn, for which the evidence remains modest.

Does hawthorn treat palpitations?

This has not been shown. The EMA recognises it only through traditional use for heart symptoms linked to nervousness, without sufficient clinical studies.

Does magnesium help you sleep?

A small trial in elderly people with insomnia found an effect on sleep, but the overall evidence remains weak.

Are there any dangers in taking Cardiocalm?

The leaflet describes no known side effect and no case of overdose has been reported. But no interaction study has been carried out, and it is not recommended under 18, during pregnancy or while breastfeeding. The real risk is masking palpitations that deserve an examination.

When should you not take Cardiocalm?

In case of allergy to hawthorn or to an excipient, under 18, during pregnancy and breastfeeding, and as long as a doctor has not ruled out a serious condition for palpitations. Seek immediate advice if you have swollen ankles or legs, chest pain or breathlessness.

What are the benefits of Cardiocalm?

According to the leaflet, it relieves temporary heart symptoms of nervous origin, mild nervous tension and minor sleep disorders, on the basis of traditional use. In 2005, the HAS judged its efficacy poorly established and its medical benefit insufficient.

What is the equivalent of Cardiocalm?

It has no generic: the public database indicates that it belongs to no generic group. Other hawthorn-based products exist, but their dose and excipients differ: ask your pharmacist for advice.

Was Cardiocalm banned in 2010?

No. A decision of 24 November 2010 by the Director General of Afssaps banned advertisements from the Pharmastra laboratory aimed at doctors, because they went beyond the authorised indications. It does not withdraw the medicine.

Our sources

  • Base de données publique des médicaments (French public medicines database; Ministry of Health, ANSM, HAS): CARDIOCALM record, film-coated tablet, CIS code 69860842, consulted on 22/11/2026, link
  • HAS, Commission de la transparence: CARDIOCALM (hawthorn), reassessment of the medical benefit, opinion of 13 April 2005, link
  • Vidal: CARDIOCALM record, Pharmastra laboratory, link
  • Décision du 24 novembre 2010 interdisant des publicités pour un médicament mentionnées à l’article L. 5122-1, premier alinéa, du code de la santé publique (decision of 24 November 2010 banning advertisements for a medicinal product, Director General of Afssaps), JORF no. 0294 of 19 December 2010, text no. 15: Légifrance
  • HAS, Commission de la transparence: opinion of 13 April 2005 on CARDIOCALM, tablet (reassessment of the medical benefit), PDF document: has-sante.fr
  • Base de données publique des médicaments: patient leaflet and SmPC of CARDIOCALM (updated 04/07/2017; SmPC sections 4.3 to 4.9 and 5.3; generic group: none), consulted on 22/11/2026.
  • EMA, HMPC: Crataegi folium cum flore, link
  • EMA, HMPC: Melissae folium, link
  • Boyle NB et al. The effects of magnesium supplementation on subjective anxiety and stress, a systematic review. Nutrients, 2017 (PubMed).
  • Abbasi B et al. The effect of magnesium supplementation on primary insomnia in elderly. J Res Med Sci, 2012 (PMID 23853635).
  • Miyasaka LS et al. Passiflora for anxiety disorder. Cochrane Database Syst Rev, 2007 (PMID 17253512).
  • Janda K et al. Passiflora incarnata in neuropsychiatric disorders, a systematic review. Nutrients, 2020 (PMID 33352740).